tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Matthew Sykes, 54 are a HOLD (34.18%), 82 are a BUY (51.9%), 22 are a SELL (13.92%).
Analyst Matthew Sykes, currently employed at GOLDMAN SACHS, carries an average stock price target met ratio of 51.58% that have a potential upside of 18.86% achieved within 81 days.
Matthew Sykes’s has documented 310 price targets and ratings displayed on 32 stocks. The coverage is on Healthcare, Basic Materials sectors.
Most recent stock forecast was given on CDNA, Caredx at 17-Jul-2024.
Analyst best performing recommendations are on ZY (ZYMERGEN).
The best stock recommendation documented was for ZY (ZYMERGEN) at 8/4/2021. The price target of $12 was fulfilled within 1 day with a profit of $3.75 (45.45%) receiving and performance score of 454.55.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
260
$16.46 (6.76%)
230.5
24 days ago
3/4 (75%)
$19.59 (8.15%)
98
Buy
295
$51.46 (21.13%)
283.69
1 months 23 days ago
8/10 (80%)
$33.62 (12.86%)
289
Hold
270
$26.46 (10.86%)
215
3 months 2 days ago
9/17 (52.94%)
$19.59 (7.82%)
198
Buy
290
$46.46 (19.08%)
260
5 months 25 days ago
4/7 (57.14%)
$44.87 (18.30%)
201
Buy
270
$26.46 (10.86%)
240
5 months 25 days ago
3/4 (75%)
$30.09 (12.54%)
171
Which stock is Matthew Sykes is most bullish on?
Which stock is Matthew Sykes is most reserved on?
What Year was the first public recommendation made by Matthew Sykes?
